Clario  and cognitive science company Cogstate  have expanded their collaboration to jointly offer data collection and quality solutions for neuroscience clinical trials.

These programmes are intended to support the requirements of neuroscience assessments for developing therapies.

The partnership steers improved data quality and detection of signals for the complete range of standard cognitive endpoints common in neuroscience trials. 

Under the alliance, the companies will merge the eCOA Multimedia technology of Clario for gathering audio, photo and patient/clinician data with a worldwide clinical network and deep therapeutic capabilities of Cogstate in neurodegenerative ailments. 

This deal will provide increased data quality benefits and operational convenience for clinicians and patients.

The latest collaboration builds on a partnership entered in July 2020 to offer digital cognitive assessments of Cogstate, along with Clario’s eCOA platform to aid in developing therapies for the central nervous system (CNS) and other ailments.

This 2020 collaboration provides a simplified solution for standard and digital outcomes with a combined approach to hardware, training and operational support.

Clario eCOA and Trial Enablement executive vice-president Andrew Cooper said: “Clinical trials, particularly those in neurodegenerative disease, require sensitive, reliable endpoints that are delivered with a streamlined, patient-centric approach, integrating the range of clinical assessments across performance-based, clinician-reported and patient-reported outcomes. 

“Fit-for-purpose eCOA functionality such as photo and audio capture and advanced workflow and scoring automations enable reliable and standardised data collection for cognitive endpoints when tightly coupled with industry-leading rater training and monitoring.”